[go: up one dir, main page]

PE20110221A1 - Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales - Google Patents

Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales

Info

Publication number
PE20110221A1
PE20110221A1 PE2011000032A PE2011000032A PE20110221A1 PE 20110221 A1 PE20110221 A1 PE 20110221A1 PE 2011000032 A PE2011000032 A PE 2011000032A PE 2011000032 A PE2011000032 A PE 2011000032A PE 20110221 A1 PE20110221 A1 PE 20110221A1
Authority
PE
Peru
Prior art keywords
complex consisting
peptidyl polymer
polypeptide complex
immunoglobulin
domain
Prior art date
Application number
PE2011000032A
Other languages
English (en)
Inventor
Dae Hae Song
Jae Hee Shin
Mi Ji Lee
Sung Hee Hong
Se Chang Kwon
Gwan Sun Lee
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41570742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of PE20110221A1 publication Critical patent/PE20110221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

REFERIDA A UN COMPLEJO DE PROTEINA QUE CONSISTE DE: a) UN POLIPEPTIDO TAL COMO HORMONAS DE CRECIMIENTO, CITOQUINAS, INTERLEUQUINAS, INMUNOTOXINAS, ENTRE OTROS; b) UN DIMERO DE PROTEINA, EL CUAL ES UN DOMINIO Fc AGLICOLADO DE INMUNOGLOBULINA TAL COMO IgG, IgA, IgD, IgE, IgM; Y QUE COMPRENDE ADEMAS UNA REGION BISAGRA; Y c) UN POLIMERO NO PEPTIDIL QUE POSEE TRES EXTREMOS TERMINALES FUNCIONALES TAL COMO POLIETILEN GLICOL, POLIPROPILEN GLICOL, POLIOXIETILADO POLIOL, ENTRE OTROS; DONDE EL DOMINIO Fc DE INMUNOGLOBULINA ESTA COMPUESTO POR UNO DE CUATRO DIFERENTES DOMINIOS SELECCIONADOS DE CH1, CH2, CH3 Y CH4. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA
PE2011000032A 2008-07-23 2009-07-23 Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales PE20110221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080071766 2008-07-23

Publications (1)

Publication Number Publication Date
PE20110221A1 true PE20110221A1 (es) 2011-04-06

Family

ID=41570742

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000032A PE20110221A1 (es) 2008-07-23 2009-07-23 Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales

Country Status (21)

Country Link
US (3) US9636420B2 (es)
EP (1) EP2300501B1 (es)
JP (1) JP5563572B2 (es)
KR (1) KR101200659B1 (es)
CN (1) CN102112493B (es)
AR (2) AR072596A1 (es)
AU (1) AU2009274738B2 (es)
BR (1) BRPI0916326A2 (es)
CA (1) CA2731546C (es)
CL (1) CL2011000079A1 (es)
ES (1) ES2523043T3 (es)
IL (1) IL210466A (es)
MX (1) MX2011000861A (es)
MY (1) MY151184A (es)
NZ (1) NZ590358A (es)
PE (1) PE20110221A1 (es)
RU (1) RU2483081C2 (es)
TW (1) TWI388570B (es)
UA (1) UA101670C2 (es)
WO (1) WO2010011096A2 (es)
ZA (1) ZA201100157B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE505551T1 (de) 2004-04-21 2011-04-15 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
PE20110221A1 (es) 2008-07-23 2011-04-06 Hanmi Science Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
KR20120002129A (ko) * 2010-06-30 2012-01-05 한미홀딩스 주식회사 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PT2726092T (pt) * 2011-06-28 2019-10-08 Lp Inhibrx Polipéptidos de fusão serpina e métodos para a sua utilização
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MX2014000316A (es) * 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
BR112014005091A2 (pt) * 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2013148871A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Engineered polypeptides
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014137161A1 (ko) * 2013-03-05 2014-09-12 한미약품 주식회사 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
KR101479937B1 (ko) * 2013-05-24 2015-01-12 주식회사 에스에프에이 글라스와 마스크의 정렬장치
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
CA3012994C (en) 2013-07-31 2020-10-20 Rinat Neuroscience Corp. Engineered polypeptide conjugates
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
KR20160145790A (ko) 2014-04-25 2016-12-20 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
JP6987741B2 (ja) * 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
US11389508B2 (en) * 2015-09-24 2022-07-19 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP4410378A3 (en) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
KR101974305B1 (ko) * 2018-02-14 2019-04-30 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022166720A1 (zh) * 2021-02-05 2022-08-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
EP4291224A4 (en) 2021-02-12 2025-01-01 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2025007086A1 (en) * 2023-06-30 2025-01-02 Loma Linda University Modified thymic stromal lymphopoietin compositions and methods of preparation and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE59109032D1 (de) 1990-06-28 1998-09-03 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
DE69233480T2 (de) 1991-02-08 2006-01-05 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
AU2400692A (en) * 1991-07-19 1993-02-23 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
EP0533006A1 (en) 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HK1042098B (zh) 1998-10-16 2009-10-30 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CA2379388C (en) 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
ATE437891T1 (de) 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
AU2002357072A1 (en) * 2001-12-07 2003-06-23 Centocor, Inc. Pseudo-antibody constructs
US20040023848A1 (en) * 2002-02-27 2004-02-05 Thomas Boehm Compositions for the treatment, prevention, and diagnosis of gastrointestinal and other infections
AU2003287131B2 (en) 2002-12-13 2008-07-24 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
EP1682582B1 (en) * 2003-11-13 2011-08-31 Hanmi Holdings Co., Ltd Method for the mass production of immunoglobulin constant region
CN101010105A (zh) * 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
PT1835938E (pt) * 2004-12-27 2013-11-06 Baxter Int Conjugados de polímero-factor de von willebrand
US20080207505A1 (en) 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP5846712B2 (ja) * 2005-08-16 2016-01-20 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 開始メチオニン残基が除去された免疫グロブリンＦｃ領域の大量生産方法
ES2548518T3 (es) * 2005-11-23 2015-10-19 Ventana Medical Systems, Inc. Conjugado molecular
MX2008014358A (es) * 2006-05-12 2008-11-24 Dong A Pharm Co Ltd Conjugado de polietilenglicol-interferon alfa.
KR20090057383A (ko) * 2006-09-15 2009-06-05 엔존 파마슈티컬즈, 인코포레이티드 다기능성 링커를 포함하는 표적화된 고분자 전구약물
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CA2676820A1 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
PE20110221A1 (es) * 2008-07-23 2011-04-06 Hanmi Science Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales

Also Published As

Publication number Publication date
TWI388570B (zh) 2013-03-11
CA2731546C (en) 2013-11-19
MY151184A (en) 2014-04-30
US9636420B2 (en) 2017-05-02
RU2011102446A (ru) 2012-08-27
EP2300501B1 (en) 2014-08-20
EP2300501A2 (en) 2011-03-30
US11040110B2 (en) 2021-06-22
BRPI0916326A2 (pt) 2020-08-25
US20110200623A1 (en) 2011-08-18
AU2009274738B2 (en) 2012-12-13
ES2523043T3 (es) 2014-11-20
JP2011529046A (ja) 2011-12-01
US10071171B2 (en) 2018-09-11
US20160051696A1 (en) 2016-02-25
KR101200659B1 (ko) 2012-11-12
WO2010011096A3 (en) 2010-05-27
US20180360983A1 (en) 2018-12-20
AR109513A2 (es) 2018-12-19
UA101670C2 (ru) 2013-04-25
IL210466A (en) 2013-08-29
AU2009274738A1 (en) 2010-01-28
TW201004649A (en) 2010-02-01
CA2731546A1 (en) 2010-01-28
IL210466A0 (en) 2011-03-31
CL2011000079A1 (es) 2011-04-29
WO2010011096A2 (en) 2010-01-28
ZA201100157B (en) 2011-10-26
RU2483081C2 (ru) 2013-05-27
JP5563572B2 (ja) 2014-07-30
NZ590358A (en) 2012-04-27
CN102112493A (zh) 2011-06-29
CN102112493B (zh) 2015-04-01
MX2011000861A (es) 2011-06-21
KR20100010919A (ko) 2010-02-02
EP2300501A4 (en) 2012-02-01
HK1154023A1 (en) 2012-04-13
AR072596A1 (es) 2010-09-08

Similar Documents

Publication Publication Date Title
PE20110221A1 (es) Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
CO2021011198A2 (es) Receptores de citocinas quiméricos constitutivamente activos
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
ATE485066T1 (de) Medizinische ballons mit modifizierten oberflächen
ECSP109940A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso
PE20210005A1 (es) Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
UY37457A (es) Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
CR20120124A (es) Moléculas de anticuerpo anti-gcc y composiciones y métodos relacionados
AR072167A1 (es) Anticuerpos contra il-6 humano y sus usos
CR10444A (es) Anticuerpo humanizado de c-kit
AR100680A1 (es) Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
CO2024004796A2 (es) Composiciones que actúan sobre bcma y métodos de uso de estas
EP3947432A4 (en) Chimeric antigen receptor (car) modulation
EP3858935A4 (en) TWO-PART CURING ADHESIVE COMPOSITION
EP4159814A4 (en) Two-pack type addition curable silicone rubber composition
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
JOP20220025A1 (ar) المواد والطرق الخاصة باستهداف مستقبلات الأجسام المضادة البوليميرية
IL310901A (en) Compositions and methods for chimeric antigen receptors specific to b cell receptors

Legal Events

Date Code Title Description
FG Grant, registration